Prostate Cancer - Results from #120

Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death. March 3, 2023

Accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging. March 3, 2023

Multi-timepoint imaging with PSMA-targeted [18F]F-Florastamin PET/CT: lesion detection and comparison to conventional imaging. March 3, 2023

Evaluation of thresholding methods for the quantification of [68Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [177Lu]Lu-PSMA-617 radioligand therapy. March 3, 2023

Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer. March 3, 2023

Retrospective Analysis of Clinical Outcomes of Stereotactic Body Radiation Therapy for Localized Prostate Cancer at an Asian Cancer Specialist Centre. March 2, 2023

A Comparison Between the Rates of Radiation Oncologist and Urologist Consultations in Men Diagnosed With Prostate Cancer in Northern Ontario, Canada. March 2, 2023

Preliminary Analysis of a Phase II Trial of Stereotactic Body Radiation Therapy for Prostate Cancer With High-Risk Features After Radical Prostatectomy. March 2, 2023

Dynamic changes in PSA levels predict prognostic outcomes in prostate cancer patients undergoing androgen -deprivation therapy: A multicenter retrospective analysis. March 2, 2023

Radiation technique and outcomes following moderately hypofractionated treatment of low risk prostate cancer: a secondary analysis of RTOG 0415. March 2, 2023

Long-term Outcomes Among Men Undergoing Active Surveillance for Prostate Cancer in Sweden. March 2, 2023

Janssen Submits New Drug Application to the U.S. Food and Drug Administration Seeking Approval of Niraparib and Abiraterone Acetate Dual-Action Tablet, Plus Prednisone, as a First-Line Targeted Treatment for Patients with mCRPC with BRCA Gene Mutations March 1, 2023

ANZUP’s Pain-Free TRUS B Trial Wins the BJUI Global Prize 2023 for Article of the Year March 1, 2023

A comprehensive comparison between mpMRI of the prostate, MR-US fusion biopsy and whole mount histopathology. March 1, 2023

Changes in prostate specific antigen (PSA) "screening" patterns by geographic region and socio-economic status in Australia: Analysis of medicare data in 50-69 year old men. March 1, 2023

Normal preoperative endogenous testosterone levels predict prostate cancer progression in elderly patients after radical prostatectomy. March 1, 2023

Potential New Approaches for Prostate Cancer Management in Resource-Limited Countries in Africa. March 1, 2023

Standardized prostate cancer incidence and mortality rates following initial non-malignant biopsy result. March 1, 2023

Urologic Oncology Survivorship Guidelines: An Overview of the Evidence and the Current Implementation Gap. February 28, 2023

Prostate-specific Membrane Antigen Positron Emission Tomography as a Biomarker to Assess Treatment Response in Patients with Advanced Prostate Cancer. February 28, 2023

Page 7 of 1288